CTOs on the Move

Arcadia Health Care

www.arcadiahomecare.com

 
Arcadia Health Care is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Haynes Ambulance Of Alabama

Haynes Ambulance Of Alabama is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hillcrest Healthcare System

Hillcrest Healthcare System is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Knoxville, TN. To find more information about Hillcrest Healthcare System, please visit www.hillcrest.com

Neighborhood Health Plan

Neighborhood Health Plan is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Memorial Healthcare System

Since its inception more than 55 years ago, Memorial Healthcare System has been a leader in providing high-quality healthcare services to South Florida residents. Today, it is the fifth-largest public healthcare system in the nation and highly regarded for its exceptional patient- and family-centered care. Memorial`s patient, physician and employee satisfaction rates are some of the most admired in the country, and the system is recognized as a national leader in quality care. To be a premier clinically integrated delivery system providing access to exceptional patient-and family-centered care, medical education, research and innovation for the benefit of the community we serve.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.